Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | DUT | P33316 | 3/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007720 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL28067259 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL22110849 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL23254274 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL8715 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL23254269 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL10349394 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL24695426 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL22110735 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| Hydrochloric Acid SCHEMBL27275372 | 0.99 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 701 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-20250170228-A1 | TERMINALLY MODIFIED RNA | ARES CAPITAL CORPORATION, AS AGENT | 2025-05-29 | — | — | US | claimed |
| CN-118005706-A | Preparation method of 2',3' -dideoxynucleotide | 天津奥利芙生物技术有限公司 | 2024-05-10 | — | — | CN | claimed |
| EP-4312942-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2022212576-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| EP-2922554-B1 | TERMINALLY MODIFIED RNA | MODERNATX INC (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-10155029-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2018-12-18 | — | — | US | claimed |
| US-5187085-A | NUCLEIC ACID SEQUENCE ANALYSIS WITH NUCLEOSIDE-5'-O-(1-THIOTRIPHOSPHATES) | APPLIED BIOSYSTEMS, INC. (US) | 1993-02-16 | — | — | US | claimed |
| EP-0500779-A1 | 4,7-DICHLOROFLUORESCEIN DYES AS MOLECULAR PROBES | THE PERKIN-ELMER CORPORATION (US) | 1992-09-02 | — | — | EP | claimed |
| EP-0496749-A1 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION. | APPLIED BIOSYSTEMS (US) | 1992-08-05 | — | — | EP | claimed |
| WO-1992006219-A1 | IMPROVED NUCLEIC ACID SEQUENCE ANALYSIS WITH NUCLEOSIDE-5'-0-(1-THIOTRIPHOSPHATES) | APPLIED BIOSYSTEMS, INC. (US) | 1992-04-16 | — | — | WO | claimed |
| WO-1991007507-A1 | 4,7-DICHLOROFLUORESCEIN DYES AS MOLECULAR PROBES | APPLIED BIOSYSTEMS, INC. (US) | 1991-05-30 | — | — | WO | claimed |
| WO-1991005060-A2 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | APPLIED BIOSYSTEMS, INC. (US) | 1991-04-18 | — | — | WO | claimed |
| EP-0407816-A2 | Base modified nucleosides | ABBOTT LABORATORIES (US) | 1991-01-16 | — | — | EP | claimed |
| US-4962193-A | ADSORPTION ON POROUS NON-POLAR RESIN, THEN SEPARATION AND ELUTION | AJINOMOTO CO., INC. (JP) | 1990-10-09 | — | — | US | claimed |
| WO-1990008155-A1 | BIOLOGICALLY REVERSIBLE PHOSPHATE AND PHOSPHONATE PROTECTIVE GROUPS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-07-26 | — | — | WO | claimed |
| US-4835104-A | Process for producing and purifying 2',3'-dideoxynucleosides, and process for producing 2',3'-dideoxy-2',3'-didehydronucleosides | AJINOMOTO CO., INC., PATENT & LICENSING DEPARTMENT (JP) | 1989-05-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155029-B2 | Terminally modified RNA | RNGTT, NSUN3, RNMT | SLC28A1 3495/4885SLC28A2 3692/4885SLC29A1 3483/4885 |
| US-20250170228-A1 | TERMINALLY MODIFIED RNA | RNGTT, NSUN3, RNMT | SLC28A1 3495/4885SLC28A2 3692/4885SLC29A1 3483/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | SLC28A1 1537/4885SLC28A2 1869/4885SLC29A1 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.